Table 8.
Evaluation of the plasma concentration of Immunoglobulin E (IgE) in mg/dL of 30 participants# at T0, T1,T2, and T3.
| Participants | T0 | T1 | T2 | T3 |
|---|---|---|---|---|
| ALC16 | 1.751 | 1.803 | 1.682 | 2.178 |
| AMB03 | 792 | 741 | 699 | * |
| BP26 | 16.725 | 15.642 | 12.703 | 10.748 |
| C-A23 | 7.998 | 6.123 | 5.904 | * |
| C-C36 | 1.982 | 2.317 | 2.168 | 2.100 |
| CL12 | 327 | 359 | 321 | 348 |
| CRS33 | 937 | 811 | 572 | 822 |
| E-S01 | 7.953 | 6.625 | 8.664 | 6.167 |
| EEV13 | 111 | 115 | 76 | 94 |
| FAS05 | 3.026 | 2.847 | 3.929 | ** |
| HFS28 | 1.393 | 1.400 | ** | ** |
| IMS35 | 4.621 | 4.633 | 5.177 | 5.571 |
| J-S42 | 29.758 | 15.186 | 14.265 | 15.187 |
| JPF18 | 28 | 1.826 | 35 | 567 |
| JSF29 | 2.931 | 3.374 | ** | ** |
| LS15 | 1.375 | 1.494 | 3.227 | 261 |
| LOF29 | 25 | 25 | 25 | 25 |
| MIV14 | 921 | 686 | 474 | 364 |
| MPG17 | 518 | 204 | 677 | 899 |
| NS07 | 1.817 | 3.405 | 4.759 | 4.777 |
| NMA30 | 1.742 | 1.306 | 954 | ** |
| PBL27 | 1.550 | 1.655 | 1.979 | ** |
| SVR04 | 209 | 239 | 315 | ** |
| TAA10 | 1.123 | 1.205 | 916 | 957 |
| VD19 | 807 | 657 | 833 | 720 |
| VAR21 | 173 | 177 | 143 | 207 |
| VAT34 | 555 | 25 | 25 | 526 |
| VDR32 | 1.994 | 1.743 | 1.635 | 1.684 |
| VLA11 | 4.889 | 5.461 | 4.995 | 4.145 |
| WN37 | 715 | 929 | 1.174 | * |
T0 before treatment (screening); T1 (30 days), T2 (60 days) during treatment, and T3 (90 days) at the end of treatment.
*Participants who did not collected material for immunogenicity analyses at that visit.
**Discontinued participants.
IgE references values for adult individuals, 1 to 183 UL/mL.
#Mislaid of material collected for immunogenicity analyzes from all visits by one participant.